Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Owlet moths (Lepidoptera: Noctuoidea) associated with Bt and non- Bt soybean in the brazilian savanna.

Luz PMC, Specht A, Paula-Moraes SV, Malaquias JV, Ferreira LFM, Otanásio PN, Diniz IR.

Braz J Biol. 2018 Jul 10. pii: S1519-69842018005017103. doi: 10.1590/1519-6984.179759. [Epub ahead of print]

2.

PrEP adopted by the brazilian national health system: What is the size of the demand?

Luz PM, Benzaken A, Alencar TM, Pimenta C, Veloso VG, Grinsztejn B.

Medicine (Baltimore). 2018 May;97(1S Suppl 1):S75-S77. doi: 10.1097/MD.0000000000010602.

3.

Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.

Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso SW, Veloso VG, Lake JE, Grinsztejn B.

J Antimicrob Chemother. 2018 May 2. doi: 10.1093/jac/dky145. [Epub ahead of print]

PMID:
29722811
4.

The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.

Luz PM, Osher B, Grinsztejn B, Maclean RL, Losina E, Stern ME, Struchiner CJ, Parker RA, Freedberg KA, Mesquita F, Walensky RP, Veloso VG, Paltiel AD.

J Int AIDS Soc. 2018 Mar;21(3):e25096. doi: 10.1002/jia2.25096.

5.

Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.

Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG; PrEP Brasil Study Team.

Lancet HIV. 2018 Mar;5(3):e136-e145. doi: 10.1016/S2352-3018(18)30008-0. Epub 2018 Feb 18.

PMID:
29467098
6.

Syndemics among individuals enrolled in the PrEP Brasil Study.

De Boni RB, Machado IK, De Vasconcellos MTL, Hoagland B, Kallas EG, Madruga JV, Fernandes NM, Cerqueira NB, Moreira RI, Goulart SP, Veloso VG, Grinsztejn B, Luz PM.

Drug Alcohol Depend. 2018 Apr 1;185:168-172. doi: 10.1016/j.drugalcdep.2017.12.016. Epub 2018 Feb 10.

PMID:
29454927
7.

Awareness of Prevention Strategies and Willingness to Use Preexposure Prophylaxis in Brazilian Men Who Have Sex With Men Using Apps for Sexual Encounters: Online Cross-Sectional Study.

Torres TS, De Boni RB, de Vasconcellos MT, Luz PM, Hoagland B, Moreira RI, Veloso VG, Grinsztejn B.

JMIR Public Health Surveill. 2018 Jan 22;4(1):e11. doi: 10.2196/publichealth.8997.

8.

Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: Systematic review and meta-analysis.

Costa JM, Torres TS, Coelho LE, Luz PM.

J Int AIDS Soc. 2018 Jan;21(1). doi: 10.1002/jia2.25066. Review.

9.

Hybrid capture as a tool for cervical lesions screening in HIV-infected women: insights from a Brazilian cohort.

Jalil EM, Luz PM, Quintana M, Friedman RK, Madeira RMDS, Andrade AC, Chicarino J, Moreira RI, Derrico M, Levi JE, Russomano F, Veloso VG, Grinsztejn B.

Braz J Infect Dis. 2018 Jan - Feb;22(1):16-23. doi: 10.1016/j.bjid.2017.10.007. Epub 2017 Dec 6.

10.

HIV testing and the care continuum among transgender women: population estimates from Rio de Janeiro, Brazil.

Jalil EM, Wilson EC, Luz PM, Velasque L, Moreira RI, Castro CV, Monteiro L, Garcia ACF, Cardoso SW, Coelho LE, McFarland W, Liu AY, Veloso VG, Buchbinder S, Grinsztejn B.

J Int AIDS Soc. 2017 Sep 19;20(1):21873. doi: 10.7448/IAS.20.1.21873.

11.

Portal vein embolization with n-butyl-cyanoacrylate through an ipsilateral approach before major hepatectomy: single center analysis of 50 consecutive patients.

Luz JHM, Luz PM, Bilhim T, Martin HS, Gouveia HR, Coimbra É, Gomes FV, Souza RR, Faria IM, de Miranda TN.

Cancer Imaging. 2017 Sep 20;17(1):25. doi: 10.1186/s40644-017-0127-3.

12.

Workplace availability, risk group and perceived barriers predictive of 2016-17 influenza vaccine uptake in the United States: A cross-sectional study.

Luz PM, Johnson RE, Brown HE.

Vaccine. 2017 Oct 13;35(43):5890-5896. doi: 10.1016/j.vaccine.2017.08.078. Epub 2017 Sep 8.

PMID:
28890192
13.

Age-standardized mortality rates related to viral hepatitis in Brazil.

Perazzo H, Pacheco AG, Luz PM, Castro R, Hyde C, Fittipaldi J, Rigolon C, Cardoso SW, Grinsztejn B, Veloso VG.

BMC Infect Dis. 2017 Jul 31;17(1):527. doi: 10.1186/s12879-017-2619-y.

14.

Towards an ideal antiretroviral regimen for the global HIV epidemic.

Grinsztejn B, Coelho LE, Luz PM, Veloso VG.

J Virus Erad. 2017 Jul 1;3(3):111-116.

15.

Substance use among HIV-infected patients in Rio de Janeiro, Brazil: Agreement between medical records and the ASSIST questionnaire.

Machado IK, Luz PM, Lake JE, Castro R, Velasque L, Clark JL, Veloso VG, Grinsztejn B, De Boni RB.

Drug Alcohol Depend. 2017 Sep 1;178:115-118. doi: 10.1016/j.drugalcdep.2017.04.033. Epub 2017 Jun 16.

16.

Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil.

Martin D, Luz PM, Lake JE, Clark JL, Campos DP, Veloso VG, Moreira RI, Cardoso SW, Klausner JD, Grinsztejn B.

J Int AIDS Soc. 2017 Jun 5;20(1):21405. doi: 10.7448/IAS.20.1.21405.

17.

High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.

Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B; PrEP Brasil Study TeamClinical Trial Number 01989611.

J Int AIDS Soc. 2017 Apr 6;20(1):21472. doi: 10.7448/IAS.20.1.21472.

18.

Thirty-day Readmission Rates in an HIV-infected Cohort From Rio de Janeiro, Brazil.

Coelho LE, Ribeiro SR, Japiassu AM, Moreira RI, Lara PC, Veloso VG, Grinsztejn B, Luz PM.

J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):e90-e98. doi: 10.1097/QAI.0000000000001352.

PMID:
28291051
19.

Liver disease and healthy life-expectancy with HIV.

Perazzo H, Luz PM.

Lancet HIV. 2017 Jun;4(6):e236-e237. doi: 10.1016/S2352-3018(17)30030-9. Epub 2017 Mar 3. No abstract available.

PMID:
28262573
20.

Age-Standardized Mortality Rates Related to Cirrhosis in Brazil from 2000 to 2012: A nationwide Analysis.

Perazzo H, Pacheco AG, De Boni R, Luz PM, Fittipaldi J, Cardoso SW, Grinsztejn B, Veloso VL.

Ann Hepatol. 2017 March-April;16(2):269-278. doi: 10.5604/16652681.1231586. No abstract available.

21.

Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil.

Grinsztejn B, Jalil EM, Monteiro L, Velasque L, Moreira RI, Garcia AC, Castro CV, Krüger A, Luz PM, Liu AY, McFarland W, Buchbinder S, Veloso VG, Wilson EC; Transcender Study Team.

Lancet HIV. 2017 Apr;4(4):e169-e176. doi: 10.1016/S2352-3018(17)30015-2. Epub 2017 Feb 8.

22.

DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.

Luz JH, Luz PM, Martin HS, Gouveia HR, Levigard RB, Nogueira FD, Rodrigues BC, de Miranda TN, Mamede MH.

Cancer Imaging. 2017 Feb 6;17(1):5. doi: 10.1186/s40644-017-0108-6.

23.

Self-rated health and substance use among individuals in HIV care in Rio de Janeiro, Brazil: a cross-sectional study.

Machado IK, Luz PM, Lake JE, Castro R, Velasque L, Clark JL, Veloso VG, Grinsztejn B, De Boni RB.

Int J STD AIDS. 2017 Oct;28(12):1175-1183. doi: 10.1177/0956462417692278. Epub 2017 Feb 2.

24.

Hospitalization rates, length of stay and in-hospital mortality in a cohort of HIV infected patients from Rio de Janeiro, Brazil.

Coelho LE, Ribeiro SR, Veloso VG, Grinsztejn B, Luz PM.

Braz J Infect Dis. 2017 Mar - Apr;21(2):190-195. doi: 10.1016/j.bjid.2016.10.007. Epub 2016 Dec 3.

25.

Partial splenic embolization to permit continuation of systemic chemotherapy.

Luz JH, Luz PM, Marchiori E, Rodrigues LA, Gouveia HR, Martin HS, Faria IM, Souza RR, Gil RA, Palladino AM, Pimenta KB, de Souza HS.

Cancer Med. 2016 Oct;5(10):2715-2720. doi: 10.1002/cam4.856. Epub 2016 Sep 9.

26.

Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study.

Coelho L, Grinsztejn B, Castilho JL, De Boni R, Quintana MS, Campos DP, Ribeiro SR, Pacheco AG, Veloso VG, Luz PM.

Lancet HIV. 2016 Oct;3(10):e490-8. doi: 10.1016/S2352-3018(16)30052-2. Epub 2016 Aug 17.

27.

Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil.

Hoagland B, De Boni RB, Moreira RI, Madruga JV, Kallas EG, Goulart SP, Cerqueira N, Torres TS, Luz PM, Fernandes NM, Liu AY, Grinsztejn B, Veloso VG; PrEP Brasil Study Team.

AIDS Behav. 2017 May;21(5):1278-1287. doi: 10.1007/s10461-016-1516-5.

PMID:
27531461
28.

Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study.

Diaz CM, Segura ER, Luz PM, Clark JL, Ribeiro SR, De Boni R, Eksterman L, Moreira R, Currier JS, Veloso VG, Grinsztejn B, Lake JE.

BMC Infect Dis. 2016 Aug 8;16:376. doi: 10.1186/s12879-016-1735-4.

29.

Poor retention in early care increases risk of mortality in a Brazilian HIV-infected clinical cohort.

Teixeira da Silva DS, Luz PM, Lake JE, Cardoso SW, Ribeiro S, Moreira RI, Clark JL, Veloso VG, Grinsztejn B, De Boni RB.

AIDS Care. 2017 Feb;29(2):263-267. Epub 2016 Jul 27.

30.

Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.

Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, MacLean RL, Parker RA, Paltiel AD, Walensky RP.

J Int AIDS Soc. 2016 Mar 29;19(1):20623. doi: 10.7448/IAS.19.1.20623. eCollection 2016.

31.

Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil.

Coelho LE, Cardoso SW, Amancio RT, Moreira RI, Ribeiro SR, Coelho AB, Campos DP, Veloso VG, Grinsztejn B, Luz PM.

BMC Infect Dis. 2016 Mar 22;16:134. doi: 10.1186/s12879-016-1462-x.

32.

Authors' Reply: Is Genotype Testing Really Cost-Effective for Primary Resistance in Brazil?

Luz PM, Grinsztejn B, Veloso VG, Paltiel AD.

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):e56. doi: 10.1097/QAI.0000000000000902. No abstract available.

33.

Retention in Early Care at an HIV Outpatient Clinic in Rio de Janeiro, Brazil, 2000-2013.

Silva DS, De Boni RB, Lake JE, Cardoso SW, Ribeiro S, Moreira RI, Clark JL, Veloso VG, Grinsztejn B, Luz PM.

AIDS Behav. 2016 May;20(5):1039-48. doi: 10.1007/s10461-015-1235-3.

34.

Time trend analysis of cervical high-risk human papillomavirus (HPV) in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil: the rise of non-16/18 HPV.

Cambou MC, Levi JE, Lake JE, de Andrade A, Jalil EM, Russomano F, Derrico M, Veloso VG, Friedman RK, Luz PM, Grinsztejn B.

Int J Infect Dis. 2015 Dec;41:17-20. doi: 10.1016/j.ijid.2015.10.017. Epub 2015 Oct 28.

35.

Monitoring of HIV treatment in seven countries in the WHO Region of the Americas.

Belaunzarán-Zamudio PF, Caro-Vega YN, Shepherd BE, Crabtree-Ramírez BE, Luz PM, Grinsztejn B, Cesar C, Cahn P, Cortés C, Wolff M, Pape JW, Padgett D, Gotuzzo E, McGowan C, Sierra-Madero JG; CCASAnet.

Bull World Health Organ. 2015 Aug 1;93(8):529-39. doi: 10.2471/BLT.14.147447. Epub 2015 May 27.

36.

Enhancing efforts to address infections.

Luz PM, Veloso VG.

Lancet HIV. 2015 Oct;2(10):e406-7. doi: 10.1016/S2352-3018(15)00151-4. Epub 2015 Aug 11. No abstract available.

PMID:
26423644
37.

Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.

Coelho L, Cardoso SW, Luz PM, Hoffman RM, Mendonça L, Veloso VG, Currier JS, Grinsztejn B, Lake JE.

Nutr J. 2015 Aug 18;14:81. doi: 10.1186/s12937-015-0072-6.

38.

Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.

Souza TM, Santini-Oliveira M, Martorelli A, Luz PM, Vasconcellos MT, Giacoia-Gripp CB, Morgado M, Nunes EP, Lemos AS, Ferreira AC, Moreira RI, Veloso VG, Siqueira M, Grinsztejn B, Camacho LA.

J Med Virol. 2016 Mar;88(3):426-36. doi: 10.1002/jmv.24351. Epub 2015 Aug 24.

PMID:
26267817
39.

CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in Latin America and the Caribbean.

Luz PM, Belaunzarán-Zamudio PF, Crabtree-Ramírez B, Caro-Vega Y, Hoces D, Rebeiro PF, Blevins M, Pape JW, Cortes CP, Padgett D, Cahn P, Veloso VG, McGowan CC, Grinsztejn B, Shepherd BE.

Open Forum Infect Dis. 2015 Jun 5;2(2):ofv079. doi: 10.1093/ofid/ofv079. eCollection 2015 Apr.

40.

Prenatal Transmission of Syphilis and Human Immunodeficiency Virus in Brazil: Achieving Regional Targets for Elimination.

Cerda R, Perez F, Domingues RM, Luz PM, Grinsztejn B, Veloso VG, Caffe S, Francke JA, Freedberg KA, Ciaranello AL.

Open Forum Infect Dis. 2015 May 22;2(2):ofv073. doi: 10.1093/ofid/ofv073. eCollection 2015 Apr.

41.

A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil.

Castilho JL, Levi JE, Luz PM, Cambou MC, Vanni T, de Andrade A, Derrico M, Veloso VG, Grinsztejn B, Friedman RK.

BMC Cancer. 2015 Jun 23;15:478. doi: 10.1186/s12885-015-1486-4.

42.

HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts.

Castilho JL, Luz PM, Shepherd BE, Turner M, Ribeiro SR, Bebawy SS, Netto JS, McGowan CC, Veloso VG, Engels EA, Sterling TR, Grinsztejn B.

Infect Agent Cancer. 2015 Feb 2;10:4. doi: 10.1186/1750-9378-10-4. eCollection 2015.

43.

A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the Caribbean.

Giganti MJ, Luz PM, Caro-Vega Y, Cesar C, Padgett D, Koenig S, Echevarria J, McGowan CC, Shepherd BE.

AIDS Res Hum Retroviruses. 2015 May;31(5):496-503. doi: 10.1089/AID.2014.0241. Epub 2015 Mar 6.

44.

Temporal Trends in Age at HIV Diagnosis in Cohorts in the United States, the Caribbean, and Central and South America.

Crabtree-Ramírez B, Vega YN, Shepherd BE, Turner M, Carriquiry G, Fink V, Luz PM, Cortes CP, Rouzier V, Padgett D, Jayathilake K, McGowan CC, Person AK.

AIDS Behav. 2015 Sep;19(9):1599-608. doi: 10.1007/s10461-014-0974-x.

45.

Factors associated with tobacco smoking and cessation among HIV-infected individuals under care in Rio de Janeiro, Brazil.

Torres TS, Luz PM, Derrico M, Velasque L, Grinsztejn E, Veloso VG, Cardoso SW, Santini-Oliveira M, Grinsztejn B, De Boni RB.

PLoS One. 2014 Dec 23;9(12):e115900. doi: 10.1371/journal.pone.0115900. eCollection 2014.

46.

Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.

Cardoso SW, Luz PM, Velasque L, Torres TS, Tavares IC, Ribeiro SR, Moreira RI, Veloso VG, Moore RD, Grinsztejn B.

BMC Infect Dis. 2014 Dec 19;14:699. doi: 10.1186/s12879-014-0699-5.

47.

Cost-effectiveness of genotype testing for primary resistance in Brazil.

Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):152-61. doi: 10.1097/QAI.0000000000000426.

48.

Anal human papillomavirus (HPV) prevalences and factors associated with abnormal anal cytology in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil.

Cambou MC, Luz PM, Lake JE, Levi JE, Coutinho JR, de Andrade A, Heinke T, Derrico M, Veloso VG, Friedman RK, Grinsztejn B.

AIDS Patient Care STDS. 2015 Jan;29(1):4-12. doi: 10.1089/apc.2014.0166. Erratum in: AIDS Patient Care STDS. 2016 Nov;30(11):528.

49.

Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.

Cardoso SW, Luz PM, Velasque L, Torres T, Coelho L, Freedberg KA, Veloso VG, Walensky RP, Grinsztejn B.

AIDS Res Ther. 2014 Sep 1;11:29. doi: 10.1186/1742-6405-11-29. eCollection 2014.

50.

Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.

Martin DA, Luz PM, Lake JE, Clark JL, Veloso VG, Moreira RI, Cardoso SW, Klausner JD, Grinsztejn B.

BMC Infect Dis. 2014 Jun 11;14:322. doi: 10.1186/1471-2334-14-322.

Supplemental Content

Support Center